<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517059</url>
  </required_header>
  <id_info>
    <org_study_id>2015_89</org_study_id>
    <secondary_id>2016-A01544-47</secondary_id>
    <nct_id>NCT03517059</nct_id>
  </id_info>
  <brief_title>Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease</brief_title>
  <acronym>Prodygi-II</acronym>
  <official_title>Prospective Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>france parkinson</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study:

        -  Longitudinal follow up of the PRODY-GI cohort for parkinson's disease (PD)

        -  Observational study of upper and lower axial symptoms' occurence in 30 PD patients in on
           and off drug conditions, 30 aged matched control subjects and 10 control subjects with
           supra nuclear palsy

        -  Multi modal approach: functional MRI, clinical , ENT assessment, respiratory assessment,
           neuropsychological and gait evaluations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, clinical assessment of :

        -  Cognition and diadochokinetic task during fMRI in 30 PD patients (in off and on
           condition)

        -  Motor assessment using VICON gait and balance analysis

        -  Pulmonary functional testing in OFF and ON drug condition

        -  Quality of life

        -  Clinical neurological MDS UPDRS , N Fog questionnaire

        -  ENT and speech therapist evaluation in OFF and ON drug condition
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the neural network between patients in OFF levodopa conditions and control subjects</measure>
    <time_frame>Between two evaluation visits, on average at 3 months (baseline- 3 months)</time_frame>
    <description>Measure evaluated by functional MRI during the realisation of a cognitive task: symbol digit modality test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the neural network between patients in OFF-drug conditions and healthy control subjects</measure>
    <time_frame>Between two evaluation visits, on average at 3 months (baseline- 3 months)</time_frame>
    <description>Measure evaluated by functional MRI during the realisation of two motor tasks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the neural network between patients in OFF-drug conditions and healthy control subjects</measure>
    <time_frame>Between two evaluation visits, on average at 3 months (baseline- 3 months)</time_frame>
    <description>Measure evaluated by resting state functional MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the neural network between OFF-drug condition and ON-drug condition in patients</measure>
    <time_frame>Between two evaluation visits, on average at 3 months (baseline- 3 months)</time_frame>
    <description>Measure evaluated by functional MRI, during the realisation of one cognitive task and two motor tasks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the neural network between patients in OFF-drug conditions and neurological control subjects (with supra nuclear palsy)</measure>
    <time_frame>Between two evaluation visits, on average at 3 months (baseline- 3 months)</time_frame>
    <description>Measure evaluated by functional MRI, during the realisation of one cognitive task and two motor tasks</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>PD patients</arm_group_label>
    <description>30 PD patients in ON and OFF levodopa conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <description>30 age matched healthy control subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurological control subjects</arm_group_label>
    <description>10 patients with defined supra nuclear palsy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Parkinson's disease (PD)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Parkinson's Disease group :

        Patients with Parkinson's Disease, who where included in the PRODYGI-1 cohort still meeting
        the MP criteria, Always followed in the service of neurology and pathology of the movement.

        Pathological control group:

          -  Patients suffering from Richardson syndrome.

          -  Aged over 18

        Healthy control group:

          -  Age-matched (± 5 years)

          -  Recruited on the basis of volunteering.

          -  free from any progressive neurological pathology after clinical examination and MoCA.

        Exclusion Criteria:

        For all groups:

          -  Pregnant or lactating woman

          -  Extra-neurological severe respiratory pathology

          -  Terminal heart failure

          -  Contraindication to MRI

          -  Refusal / withdrawal / inability to give consent

          -  ENT pathology.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline MOREAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline MOREAU, MD</last_name>
    <phone>3.20.44.67.52</phone>
    <phone_ext>+33</phone_ext>
    <email>caroline.moreau@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHRU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Caroline Moreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Levodopa</keyword>
  <keyword>axial symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dysarthria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

